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We aimed to evaluate the relationship between insulin pharmacodynamics and glycaemic out-
comes during closed-loop insulin delivery and sensor-augmented pump therapy. We retrospec-
tively analysed data from a multicentre randomized control trial involving 32 adults with type
1 diabetes receiving day-and-night closed-loop insulin delivery and sensor-augmented pump
therapy over 12 weeks. We estimated time-to-peak insulin action (tmax,IA) and insulin sensitivity
(SI) during both interventions, and correlated these with demographic factors and glycaemic
outcomes. During both interventions, tmax,IA was positively correlated with pre- and post-
intervention HbA1c (r = 0.50-0.52, P < .01) and mean glucose (r = 0.45-0.62, P < .05), and
inversely correlated with time sensor glucose, which was in target range 3.9 to 10 mmol/L
(r = −0.64 to −0.47, P < .05). Increased body mass index was associated with higher tmax,I and
lower SI (both P < .05). During closed-loop insulin delivery, tmax,IA was positively correlated with
glucose variability (P < .05). Faster insulin action is associated with improved glycaemic control
during closed-loop insulin delivery and sensor-augmented pump therapy.
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1 | INTRODUCTION
Rapid-acting insulin analogues are widely used in insulin pump-
treated type 1 diabetes and closed-loop insulin delivery systems.1
However, little is known about the association between its phar-
macodynamics, and demographic factors and glycaemic outcomes
during closed-loop insulin delivery and sensor-augmented pump
therapy.
2 | METHODS
We retrospectively analysed data obtained from a multicentre (UK,
Germany and Austria), randomized crossover study involving 32 parti-
cipants with type 1 diabetes and conducted in free-living home set-
tings.2 Participants were randomly assigned to receive 12 weeks of
automated closed-loop insulin delivery first and sensor-augmented
pump therapy (open-loop) second, or vice versa applying rapid-acting
insulin analogue, aspart or lispro, to follow their pre-study insulin use.
Day-and-night closed-loop insulin delivery was applied using a hybrid
approach, during which participants administered prandial insulin
using standard pump bolus wizard. The participants underwent 4 to
6 weeks of run-in period using the study insulin pump and real-time
continuous glucose monitoring device prior to randomization to fully
optimize insulin delivery.
Using a validated modelling approach analysing continuous glu-
cose monitoring, insulin delivery and meal content data (outlined in
File S1),3 we estimated time-to-peak insulin action (tmax,IA; repre-
senting time to maximum insulin action) and insulin sensitivity (SI;
representing glucose-lowering potency of insulin) during closed-
loop and open-loop interventions. The approach utilized compart-
ment modelling of insulin absorption and action, meal absorption
dynamics and glucose dynamics. Parameters were estimated using
Bayesian estimator and checked for normality. The validity of the
model was evidenced by the physiological plausibility of model
parameters, good model fit and the ability to reproduce independ-
ent clinical data.3 Pearson correlation coefficient was used to relate
these model-derived parameters, demographic factors and glycae-
mic outcomes, which included age, body mass index (BMI), pre-
and post-intervention HbA1c, mean glucose, time with sensor glu-
cose in the target range between 3.9 and 10 mmol/L, and glucose
variability expressed as the coefficient of variation (CV). P-values
less than .05 were considered statistically significant. Statistical
analyses were performed using SPSS (IBM Software, Hampshire,
UK, version 21). Data are reported as mean (SD), unless stated
otherwise.
3 | RESULTS
Data from 32 adults with type 1 diabetes [male 17, age 39.9
(9.5) years, BMI 25.4 (4.4) kg/m2, duration of diabetes 21.2
(9.3) years, duration of pump use 7.9 (6.0) years] were analysed.
We estimated time-to-peak insulin action and insulin sensitivity in
32 closed-loop participants and 28 open-loop participants; four
open-loop participants’ datasets were excluded from the final
analysis due to insufficient data (less than 50 days of continuous
glucose-monitoring data) deemed appropriate for accurate subject-
level parameter estimates. Time-to-peak insulin action and insulin
sensitivity were 79 (12) minutes and 4.7 (1.2) 10−3 mM/min per
mU/L during the closed-loop intervention, and 72 (14) minutes
and 4.2 (1.1) 10−3 mM/min per mU/L during the open-loop inter-
vention. No statistically significant differences were observed
between parameters estimated during open-loop and closed-loop
interventions (Table S1, File S1), supporting the validity of the
estimates.
Table 1 reports the Pearson correlation coefficients between
time-to-peak insulin action and insulin sensitivity, and demographic
factors and glycaemic outcomes. During both interventions, time-to-
peak insulin action was positively correlated with pre- and post-
intervention HbA1c (P < .01) and mean glucose levels (P < .05-.01),
whilst being inversely correlated with time sensor glucose, which was
in target range of 3.9 to 10 mmol/L (P < .05-.01). A higher BMI was
associated with higher time-to-peak insulin action (P < .05-.01) and
lower insulin sensitivity (P < .05). A positive correlation was observed
between time-to-peak insulin action and glucose variability during
closed-loop (P < .05) but not during open-loop intervention. No other
relationship was observed. Figure 1 shows scatter plots of time-to-
peak insulin action vs post-intervention HbA1c for the
2 interventions.
4 | DISCUSSION
We estimated time-to-peak insulin action and insulin sensitivity in
adults with type 1 diabetes during 12-week closed-loop insulin deliv-
ery and conventional insulin pump therapy, and demonstrated asso-
ciations with clinical factors of interest.
Time-to-peak insulin action reflects the timespan for the subcu-
taneously delivered rapid-acting insulin to reach the peak glucose-
lowering effect. The population estimates 79 minutes during the
closed-loop intervention and 72 minutes during sensor-augmented
insulin therapy, which compares well with 90 to 100 minutes4 meas-
ured during glucose clamp studies when higher insulin doses were
administered resulting in endogenous glucose production to be maxi-
mally suppressed and the measurements reflecting primarily slower
insulin action through augmentation of glucose disposal in the mus-
cle. During both interventions, significant correlations were observed
between time-to-peak insulin action and glycaemic outcomes includ-
ing pre- and post-intervention HbA1c, mean glucose and percentage
of time spent with glucose in the target range. These correlations
suggest that faster insulin absorption may be associated with
improved glycaemic control, and that acceleration may provide fur-
ther benefit. The observation is in agreement with previous findings
that showed that treatment with rapid-acting insulin analogues in
type 1 diabetes resulted in improved glucose control compared with
regular human insulin,5–7 even under the condition that regular
human insulin meal time bolus was titrated 30 minutes ahead of
meals whilst rapid-acting insulin bolus was titrated at meal time. The
sole difference between rapid-acting insulin and regular human
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insulin is the faster insulin absorption and thus action. A recent trial
evaluated the efficacy of faster-acting insulin aspart and demon-
strated a greater reduction in HbA1c (−0.15%) for meal time faster
aspart compared with insulin aspart after 26 weeks treatment.8 The
time-to-maximum plasma insulin concentration of faster-acting insulin
aspart is 26 minutes left-shifted compared with that of insulin aspart
during insulin pump therapy.9 The highly significant correlation
between time-to-peak insulin action and mean glucose levels accounts
for about 40% of the between-subject variability in glucose levels.
A positive correlation between time-to-peak insulin action and
glucose variability was observed during closed-loop but not open-
loop intervention. The clinical significance of the correlation might
have been “diluted” during open-loop as basal insulin delivery was
less variable. The higher variability of basal insulin delivery during
closed-loop accentuated the importance of faster insulin absorption
and action.
Faster insulin action was associated with a lower BMI. A similar
trend was previously reported between subcutaneous absorption of
insulin aspart and BMI.10 Increasing subcutaneous adiposity is
expected to result in reduction of subcutaneous blood flow and the
rate of absorption of rapid-acting insulin and the peak time of insulin
action.
In our previous study, we reported the variability of individual
insulin requirements during closed-loop intervention.11 When time-
to-peak insulin action was correlated with variability of insulin
requirements, slower insulin action was found to be associated with
more variable overnight insulin requirements (r = .55, P = .001). This
suggests that slower insulin action may provide a further challenge to
optimize overnight insulin rate during conventional pump therapy.
Insulin sensitivity was estimated at 0.0047 and 0.0042 mM/min
per mU/L during the closed-loop and open-loop interventions,
respectively. These estimates are in concordance with published data
reporting 0.0005/min per mU/L at a glucose concentration of 8 to
10 mmol/L.12 However, we have not compared our estimates of
insulin sensitivity with those obtained with the gold standard eugly-
caemic hyperinsulinaemic clamp test. We observed a negative corre-
lation between insulin sensitivity and BMI in agreement with
previously reported data in adults with type 1 diabetes.13
The main novelty of the present study is the finding of the positive
correlation between time-to-peak insulin action and HbA1c level, which
highlights the need for new insulin formulations or other novel delivery
methods that could result in faster insulin absorption and action. The
development of faster-acting insulin aspart,9 inhaled insulin14 and infu-
sion site warming devices15 may contribute towards this goal. These
new formulations and delivery methods may benefit both conventional
insulin pump therapy and the closed-loop insulin delivery system.
In conclusion, faster insulin action was associated with better
glycaemic control during closed-loop insulin delivery and sensor-
augmented pump therapy, justifying further research to be directed
towards accelerating insulin absorption and action.
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